Coherus Oncology CHRS 深 滬
等待開盤 10-08 09:30:00 美东时间
1.01
-0.020
-1.94%
華盛通- 最 高1.08
- 今 開1.02
- 成交量 121.87万股
- 最 低 1.01
- 昨 收 1.03
- 總市值 1.56亿
- 52周最高 2.6158
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 1.01
- 委 比 94.24%
- 總股本 1.55亿
- 歷史最高 38.10
- 量 比 0.72
- 振 幅 6.80%
- 歷史最低 0.6603
- 每 手 1
- 風險率 0.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Coherus Oncology has retained Oppenheimer as its financial advisor to market and sell its Legacy BioSim Assets, which include patents, intellectual property, royalties, cell lines, and related materials. The company also announced the distribution of Contingent Value Rights (CVRs) to its shareholders, entitling them to a share of proceeds from the sale or licensing of these assets. The CVRs will be distributed on October 7, 2026, to shareholders ...
09-23 13:30
Coherus Oncology Reveals Special Dividend of Biosimilar Contingent Value Rights; Company Intends To Immediately Commence A Sale Process For The Legacy Biosim Assets
Coherus Oncology, Inc. (NASDAQ:CHRS) ("Coherus", "Coherus Oncology" or the "Company") today announced a special dividend of contingent value rights (each, a "CVR" and collectively, the "CVRs"), which will be distributed on a pro rata basis to stockholders of record of the Company’s common stock as o...
08-18 05:37
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology announced a special dividend of contingent value rights (CVRs) to its stockholders, distributed on October 7, 2026, based on ownership as of September 30, 2026. The CVRs entitle holders to a share of net proceeds from the sale of the company's remaining biosimilar assets, including patents, intellectual property, royalties, cell lines, and related materials. This move aims to complete the transformation of Coherus Oncology into a...
08-17 21:33
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $12 to $10.
08-08 01:08
Coherus BioSciences Q2 Adj. EPS $(0.19) Beats $(0.20) Estimate, Sales $14.307M Miss $14.400M Estimate
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 44.12 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $14.307 millio...
08-06 04:29
Coherus Oncology 2026年第二季度财报：LOQTORZI增长推动亏损收窄
Coherus Oncology 2026年第二季度净营收1,430.7万美元，同比增长约40%；持续经营业务每股亏损0.22美元，LOQTORZI收入增长37%，但经营现金流净流出扩大至6,209万美元。
08-05 22:21
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
Coherus Oncology (CHRS) announced it will release its Q2 2026 financial results on August 5, 2026, followed by a conference call and webcast at 5:00 p.m. EDT. The call will discuss financial results and business updates. Pre-registration is required for dial-in access, and a webcast replay will be available on the company's investor website. Coherus focuses on expanding its oncology product portfolio, including its approved PD-1 inhibitor LOQTORZ...
07-22 17:36
Coherus Announces Clinical Collaboration And Supply Agreement With Zumutor To Conduct Phase 1 Trial Of ZM008, NK Checkpoint Anti-LLT1 Monoclonal Antibody In Combination With LOQTORZI
Coherus Oncology, Inc. (NASDAQ:CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical collaboration and supply agreement to conduct a Phase 1 trial of ZM008, a novel NK checkpoint anti-LLT1 monoclonal antibody in combination with LOQTORZI (toripa...
06-24 02:02
